Search Results

An analysis of the 2022 DAWN data presents: (1) nationally representative weighted estimates of all drug-related emergency department (ED) visits, (2) nationally representative weighted estimates of the top substances involved in drug-related ED visits, including rates by race and ethnicity; (3) nationally representative weighted estimates of opioid-related ED visits...

This short report uses data from the Drug Abuse Warning Network (DAWN) to examine the emergency department (ED) visits for children aged 1 -5 that involved opioid pain relievers. Hydrocodone (Vicodin, Lortab), oxycodone (OxyContin, Percocet), and codeine are examples of opioid pain relievers; buprenorphine (Suboxone), is an opioid that is...

There has been a significant increase in hospitalizations for opioid misuse in recent years. Using 2010-2014 MarketScan commercial data, this report finds that 40 percent of patients do not receive any follow-up services within 30 days after an opioid-related hospitalization. Only 11 percent of patients received the recommended combination of...

Describes emergency department (ED) visits involving the nonmedical use of narcotic pain relievers (opioids) using data from the Drug Abuse Warning Network (DAWN). The drugs most commonly combined with narcotic pain relievers in ED visits; trends for narcotic pain relievers (2005-2011); demographic characteristics of narcotic pain reliever-related visits in 2011...

This short report examines emergency department (ED) visits involving benzodiazepines, which are medications prescribed to relieve symptoms of anxiety, panic attacks and seizures. It looks at the effect of combining benzodiazepines with opioid pain relievers or alcohol, both substances that also depress the central nervous system. The report quantifies the...